title: Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
abstract: Obesity, poor growth, and hypotonia in children with Prader-Willi syndrome (PWS) are accompanied by abnormal body composition resembling a GH-deficient state. Hypothalamic dysfunction in PWS includes decreased GH secretion, suggesting a possible therapeutic role for GH treatment. While short-term benefits of treatment with GH have been shown, whether these beneficial effects are dose dependent and persist or wane with prolonged therapy remains uncertain. Effects of 24 additional months of GH treatment at varying doses (0.3, 1.0, and 1.5 mg/m(2).d) on growth, body composition, strength and agility, pulmonary function, resting energy expenditure (REE), and fat utilization were assessed in 46 children with PWS, who had previously been treated with GH therapy (1 mg/m(2).d) for 12-24 months. Percent body fat, lean muscle mass, and bone mineral density (BMD) were measured by dual x-ray absorptiometry. Indirect calorimetry was used to determine REE and to calculate respiratory quotient. A modified Bruininks-Oseretski test of physical performance evaluated strength and agility. During months 24-48 of GH therapy, continued beneficial effects on body composition (decrease in fat mass and increase in lean body mass), growth velocity, and REE occurred with GH therapy doses of 1.0 and 1.5 mg/m(2).d (P < 0.05), but not with 0.3 mg/m(2).d. BMD continued to improve at all doses of GH (P < 0.05). Prior improvements in strength and agility that occurred during the initial 24 months were sustained but did not improve further during the additional 24 months regardless of dose. Salutary and sustained GH-induced changes in growth, body composition, BMD, and physical function in children with PWS can be achieved with daily administration of GH doses > or =1 mg/m(2). Lower doses of GH, (0.3 mg/m(2).d) effective in improving body composition in GHD adults, do not appear to be effective in children with PWS at sustaining improvement in body composition.
authors.affiliation: Department of Pediatrics, University of Wisconsin Children's Hospital, Madison, Wisconsin 53792, USA. alcarrel@facstaff.wisc.edu
authors.forename: Aaron L
authors.initials: AL
authors.lastname: Carrel
authors.forename: Susan E
authors.initials: SE
authors.lastname: Myers
authors.forename: Barbara Y
authors.initials: BY
authors.lastname: Whitman
authors.forename: David B
authors.initials: DB
authors.lastname: Allen
mesh_terms: D000293:Adolescent; D001786:Blood Glucose / Q000032:analysis; D001823:Body Composition; D015519:Bone Density; D002648:Child; D002664:Child Nutritional Physiological Phenomena; D004334:Drug Administration Schedule; D004734:Energy Metabolism; D005260:Female; D006128:Growth; D013006:Growth Hormone / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008055:Lipids / Q000097:blood; D008137:Longitudinal Studies; D008297:Male; D009048:Motor Skills; D018482:Muscle, Skeletal / Q000503:physiopathology; D011218:Prader-Willi Syndrome / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
chemical_list: D001786:Blood Glucose; D008055:Lipids; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone